A Quantitative Clinicopathological Signature for Predicting Recurrence Risk of Pancreatic Ductal Adenocarcinoma After Radical Resection

Chaobin He¹, Xin Huang¹, Yu Zhang²†, Zhiyuan Cai¹, Xiaojun Lin¹ and Shengping Li¹*

¹State Key Laboratory of Oncology in South China, Department of Hepatobiliary and Pancreatic Surgery, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, ²State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China

Recurrence and distant metastases were main reasons of unfavorable outcomes for patients with pancreatic ductal adenocarcinoma (PDAC) after surgery. The aim of this study was to describe the patterns, timing, and predictors of recurrence or metastasis in PDAC patients after curative surgery. Patients with PDAC who underwent radical pancreatectomy were included. Associations between clinicopathological and radiological characteristics and specific pattern of progression were investigated. Least absolute shrinkage and selection operator (LASSO) and Cox regression were applied to assess the prognostic factors for overall survival (OS) and progression-free survival (PFS). A total of 302 patients were included into present study, and 173 patients were documented as recurrence after a median survival of 24.7 months. More than half of patients recurred after 12 months after surgery, and the liver was the most common metastatic site. Decreased time interval to progression, elevated carbohydrate antigen 19-9 (CA19-9) level, and lymph node (LN)16 metastasis were independent predictors for reduced OS. Independent prognostic factors for PFS included elevated carcinoembryonic antigen (CEA) level, local progression, liver or lung-only metastasis, local + distant progression, multiple metastases, LN16 metastasis, imaging tumor size, chemotherapy, and tumor–node–metastasis (TNM) stage. The predictive system showed valuable prediction performance with values of concordance indexes (C-indexes) and the area under the receiver operating characteristic curve (AUC) over 0.80. Different survival curves and predictive factors for specific patterns of disease progression suggested the biological heterogeneity, providing new versions into personal management of recurrence in PDAC patients after surgery.

Keywords: pancreatic ductal adenocarcinoma, recurrence, pattern, timing, predictor

INTRODUCTION

Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease and is predicted to become the second leading cause of cancer-specific death by 2030 (1). Surgery followed by adjuvant chemotherapy has been widely established as the best mean to obtain longer survival. However, this combination therapy can only be applied to 20% of patients, whereas most patients suffered from locally...
advanced or metastatic diseases, owing to the lack of early clinical symptoms and effective screening methods. Moreover, even after curative resection, up to 80% of patients suffered from recurrence soon after surgery (2–4), and the 5-year survival rate was <6% (5).

Progression had a truly negative effect on prognoses of patients with PDAC. However, the variations of biological behaviors and clinicopathological factors of tumors would contribute to different patterns and timing of progression even when diseases were classified as the same stages. Although multiple studies illustrated the risk factors of progression, such as resection margin status and lymph node (LN) metastasis (6, 7), the relationship between the prognosis and progression was rarely evaluated for patients with PDAC. The prognosis might be changing among patients with different patterns and timing of progression, whereas significant heterogeneity existed among the current reports regarding patterns and timing of recurrence owing to the small sample sizes and limited period of follow-up (8, 9). Understanding both the risk factors and the patterns of progression of PDAC patients can provide an insight into optimization of the treatment, as well as the surveillance strategies. Although recurrence was associated with decreased survival, whether the sites and timing of recurrence had different influences on survival remained controversial. Thus, the aim of this study was to evaluate the risk factors for different patterns of recurrences and compare the survival differences in PDAC patients with varied patterns or timing of disease progression.

MATERIALS AND METHODS

Patients
This study included consecutive patients with PDAC who underwent surgical resection at Sun Yat-sen University Cancer Center (SYSUCC) between 2008 and 2018. Excluded patients were those with metastatic diseases detected at diagnosis by radiological examination, such as computed tomography (CT) and magnetic resonance imaging (MRI). Positron emission tomography/CT (PET/CT) and diagnostic laparoscopy were also selectively performed to detect metastases on the basis of the recommendation of the pancreatic multidisciplinary team. The resection margin for radical margin was defined as 1.5–2 mm, which was the same as that of previous studies (10, 11). Excluded were also patients with microscopic or macroscopic incomplete resection, a history of secondary tumors, period of follow-up <1 year, and missing follow-up records.

Data Collection
Resectability was judged on the basis of CT or MRI, and staging was determined by the pathological factors in accordance with the 8th edition of American Joint Committee on Cancer staging system (12, 13). A team specialized in pancreatic surgery performed all radical pancreatic resection. An experienced pancreatic pathologist assessed all the surgical specimens, made the diagnosis of PDAC, and described the pathological variables, including tumor site, tumor size, tumor differentiation, T-stage, LN status (N-stage), LN total number, positive LN number, macrovascular invasion, microvascular invasion, lymph vessel invasion, perineural invasion, adjacent organ invasion, and satellite foci. LN ratio (LNR) was defined as the number of LNs with metastases divided by the total number of excised LNs. Several radiological variables, including imaging tumor size, LN metastasis, vascular invasion, and LN size, were analyzed. Inflammation-based indexes, such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), modified Glasgow Prognostic Score (mGPS), prognostic nutritional index (PI), PI, and systemic immune-inflammation index (SII), were included in this study and calculated according to previous studies (14, 15). Clinical data were also analyzed in this study, including age, gender, white blood cell (WBC) count, C-reactive protein (CRP), albumin (ALB), serum levels of carbohydrate antigen 19-9 (CA19-9), and carcinoembryonic antigen (CEA).

Follow-Up and Recurrence
The follow-up of patients occurred at the outpatient clinic of our hospital. In general, follow-up strategies consisted of regular chest CT, abdominal CT, and CA19-9 test at least every 2 months during the first year after surgical resection and every 3 months thereafter. Occasional additional imaging modalities, such as MRI and PET/CT, were selectively performed to determine patterns of recurrence. Follow-up data were retrieved at the end of May 2019. The categories of regression patterns in the study conducted by Groot et al. (4) were adopted in this study. When considering patterns of recurrence, only the first location of recurrence was documented, and local recurrence and distant recurrence were registered, separately. In addition, distant recurrences were judged as “liver-only” and “lung-only” recurrences for the isolated hepatic and pulmonic recurrence, respectively, and “others” for isolated recurrence in other less common locations. If both local recurrence and isolated distant metastasis occurred or multiple distant metastases were detected at the same time, recurrences were defined as “local + distant” and “multiple” recurrences, respectively.

Survival Outcomes and Statistical Analysis
Progression-free survival (PFS) and overall survival (OS) were defined as the duration from the date of surgery until the date when tumor progression was diagnosed and death, respectively, or last follow-up. Post-progression survival (PPS) was defined as the time from the first recurrence to either death or last follow-up. Survival time was estimated using the Kaplan–Meier method, and the subgroup differences were compared with log-rank test. Univariate analyses were performed to describe the association between clinical, pathological, and radiological factors and specific patterns of recurrence. For PFS and OS prediction, multivariate logistic regression was conducted on the basis of clinical characteristics and pathological or radiological variables selected by least absolute shrinkage and selection operator (LASSO) logistic regression model. The prediction algorithms were further validated using receiver operating characteristic (ROC) curves. Area under the ROC curve (AUC) and concordance index (C-index) of the multivariate-regression models were calculated and compared. Two-tailed P < 0.05 were considered statistically significant. All statistical
analyses were conducted using R software version 3.2.5 (R Development Core Team; http://www.r-project.org).

RESULTS

Patient Characteristic

From 2008 to 2018, a total of 355 patients underwent radical pancreaticoduodenectomy (PD) or distal pancreatectomy for histologically confirmed PDAC. Excluded from this cohort were 10 patients with microscopic or macroscopic incomplete resection, 12 patients with second primary tumors, and 31 patients with incomplete follow-up information. Consequently, 302 patients were included into this study. All patients were followed up at least 1 year. At the end of follow-up, 195 patients (64.6%) were alive after a median follow-up of 24.7 months (95% confidence interval [CI] 20.3–29.1) from surgery. Recurrence was documented in 173 patients (57.3%), whereas 129 patients (42.7%) had no signs of recurrence. The median follow-up time for patients with and without tumor progression was 13.8 and 40.6 months, respectively.

Timing of Recurrence

Among 173 patients who had recurrence, 18 patients had done so within 6 months, 26 within 6–12 months, 57 within 12–24 months, and 72 beyond 24 months after surgery. There were no significant differences in ages and sexes among patients in different recurrent time groups. Primary tumors in early recurrence groups were larger, more likely to be poorly differentiated, and diagnosed at more advanced local stages. Patients with early recurrence had more often T4 tumors, more metastatic LNs, and more often para-aortic LNs (LN16) metastasis than had those in late recurrence groups (Table 1). Median PFS was 11.8 months (95% CI 10.2–15.3) for the whole cohort and 7.0 months (95% CI 6.2–8.4) for those who developed recurrences. For patients who developed recurrences, the comparisons of PPS and OS stratified by different time intervals of recurrences are shown in Figure 1. It was shown that median OS and PPS for patients who developed recurrences. For patients who developed recurrences, the pairwise comparisons of OS and PPS were conducted (Supplement Tables 1–4). Figures 2A and 2B show medians and 95% CIs for OS and PPS of all patients, respectively. Age older than 60 years differed significantly at progressive time points. However, of these recurrent patterns is shown in Figure 2. Liver-only progressions occupied the majority of all progressions within 6 months, whereas they were responsible for just 12.5% of all recurrences after 24 months since surgery (P < 0.001). Also, liver-only progression diminished over time, and recurrences of other sites became more and more common 1 year later since surgery.

Patients with different progression patterns had significantly different cumulative recurrence rates in different time periods after surgery (Supplement Figure 1). It was shown that cumulative rates of liver metastasis were significantly higher than those of local and other sites of progression, whereas the cumulative rates of liver, lung, and local plus distant and multiple metastases were comparable. The pairwise comparisons of OS and PPS (Supplement Figure 2), and PFS (Figure 4) for patients with different recurrence patterns were conducted. Median OS for patients with local recurrence (29.4 months, 95% CI 24.5–39.6) was significantly longer than that of patients with multiple progressions (17.5 months, 95% CI 11.2–19.5), whereas patients with other recurrence patterns of progression had similar OS rates. Similar results of survival comparisons were observed for PPS. In terms of PFS, patients with local (9.0 months, 95% CI 6.4–10.6) and other sites of progressions (12.7 months, 95% CI 9.1–28.7) had similar median survival, whereas they were both higher than those with other patterns of progressions.

Risk Factors for Different Patterns of Recurrence

Results of univariate and multivariate logistic regression models for local recurrence and liver-only metastasis are shown in Tables 2, 3, respectively. Also, risk factors of lung only, other sites of metastasis, local + distant, and multiple metastases are shown in Supplement Tables 1–4, respectively. Age older than 60 years was a strong predictor for both liver-only metastasis (hazard ratio [HR] = 1.35, 95% CI 1.21–1.73, P = 0.031) and multiple metastases (HR = 9.82, 95% CI 1.20–80.66, P = 0.033). Specific stations of LN metastases were significantly associated with different patterns of progressions, including LN15 metastasis as a predictor for liver-only (HR = 6.39, 95% CI 1.29–31.52, P = 0.023) and local + distant metastases (HR = 8.51, 95% CI 1.27–59.11, P = 0.030), LN18 metastasis as a predictor for local progression (HR = 8.97, 95% CI 1.48–54.23, P = 0.017), LN10 metastasis as a predictor for lung-only metastasis (HR = 15.96, 95% CI 1.89–134.86, P = 0.011), and LN14 metastasis as a predictor for multiple metastases (HR = 7.38, 95% CI 1.61–33.74, P = 0.010). Patients receiving adjuvant chemotherapy had a decreased likelihood of local progression (HR = 0.18, 95% CI 0.08–0.42, P < 0.001) and lung-only metastasis (HR = 0.14, 95% CI 0.02–0.83, P = 0.031) than those who did not receive adjuvant chemotherapy. Also, PLR was the only independent predictor for other sites of metastases (HR = 0.13, 95% CI 0.02–0.87, P = 0.036), and enlarged imaging LN size was found to increase the likelihood of local + distant metastases (HR = 4.57, 95% CI 1.34–15.60, P = 0.015).
| Characteristics | Diagnosis of progression | Characteristics | Diagnosis of progression |
|-----------------|-------------------------|-----------------|-------------------------|
|                 | N | Absence | 2–6 M | 6–12 M | 12–24 M | >24 M | P            | N | Absence | 2–6 M | 6–12 M | 12–24 M | >24 M | P            |
| Whole cohort    | 302 | 129 | 18 | 26 | 57 | 72 | 0.670 | 302 | 129 | 18 | 26 | 57 | 72 |
| Age ≤60 years   | 164 | 74 | 8 | 12 | 29 | 41 | 0.286 | 146 | 70 | 8 | 13 | 21 | 34 | 0.287 |
| Age >60 years   | 138 | 55 | 10 | 14 | 28 | 31 | Presence | 156 | 59 | 10 | 13 | 36 | 38 |
| Gender Female   | 119 | 53 | 7 | 13 | 25 | 21 | Presence | 170 | 119 | 15 | 24 | 52 | 60 | 0.284 |
| Gender Male     | 183 | 76 | 11 | 13 | 32 | 51 | Presence | 34 | 10 | 3 | 2 | 5 | 12 |
| Recurrence Absence | 174 | 129 | 10 | 11 | 11 | 13 | <0.001 | 173 | 83 | 12 | 17 | 26 | 35 | 0.038 |
| Recurrence Presence | 128 | 0 | 8 | 15 | 46 | 59 | Presence | 115 | 56 | 6 | 11 | 23 | 31 |
| Recurrence patterns Absence | 174 | 129 | 10 | 11 | 11 | 13 | <0.001 | 173 | 83 | 12 | 17 | 26 | 35 | 0.038 |
| Recurrence patterns Presence | 128 | 0 | 8 | 15 | 46 | 59 | Presence | 115 | 56 | 6 | 11 | 23 | 31 |
| Local LN metastasis Absence | 174 | 83 | 13 | 17 | 26 | 35 | 0.035 | 173 | 83 | 12 | 17 | 26 | 35 | 0.038 |
| Local LN metastasis Presence | 128 | 46 | 5 | 9 | 31 | 37 | Presence | 115 | 56 | 6 | 11 | 23 | 31 |
| LNM5 metastasis Absence | 300 | 127 | 18 | 26 | 57 | 72 | 0.609 | 287 | 123 | 18 | 26 | 55 | 65 | 0.197 |
| LNM5 metastasis Presence | 2 | 2 | 0 | 0 | 0 | 0 | Presence | 115 | 56 | 6 | 11 | 23 | 31 |
| LNM6 metastasis Absence | 298 | 126 | 18 | 26 | 57 | 71 | 0.672 | 287 | 123 | 18 | 26 | 55 | 65 | 0.197 |
| LNM6 metastasis Presence | 4 | 3 | 0 | 0 | 1 | 0 | Presence | 115 | 56 | 6 | 11 | 23 | 31 |
| LN7 metastasis Absence | 296 | 128 | 17 | 25 | 56 | 70 | 0.582 | 287 | 123 | 18 | 26 | 55 | 65 | 0.197 |
| LN7 metastasis Presence | 6 | 1 | 1 | 1 | 1 | 2 | Presence | 115 | 56 | 6 | 11 | 23 | 31 |
| LN8 metastasis Absence | 294 | 126 | 17 | 25 | 57 | 68 | 0.561 | 287 | 123 | 18 | 26 | 55 | 65 | 0.197 |
| LN8 metastasis Presence | 8 | 3 | 1 | 1 | 0 | 3 | Presence | 115 | 56 | 6 | 11 | 23 | 31 |
| LN9 metastasis Absence | 292 | 125 | 17 | 25 | 57 | 68 | 0.492 | 287 | 123 | 18 | 26 | 55 | 65 | 0.197 |
| LN9 metastasis Presence | 10 | 4 | 1 | 1 | 0 | 4 | Presence | 115 | 56 | 6 | 11 | 23 | 31 |
| LN10 metastasis Absence | 295 | 127 | 17 | 26 | 56 | 69 | 0.566 | 287 | 123 | 18 | 26 | 55 | 65 | 0.197 |
| LN10 metastasis Presence | 7 | 2 | 1 | 0 | 1 | 3 | Presence | 115 | 56 | 6 | 11 | 23 | 31 |
| LN11 metastasis Absence | 294 | 126 | 18 | 26 | 56 | 68 | 0.436 | 287 | 123 | 18 | 26 | 55 | 65 | 0.197 |
| LN11 metastasis Presence | 8 | 3 | 0 | 0 | 1 | 4 | Presence | 115 | 56 | 6 | 11 | 23 | 31 |
| LN12 metastasis Absence | 268 | 116 | 18 | 23 | 49 | 62 | 0.493 | 287 | 123 | 18 | 26 | 55 | 65 | 0.197 |
| LN12 metastasis Presence | 34 | 13 | 0 | 0 | 3 | 10 | Presence | 115 | 56 | 6 | 11 | 23 | 31 |
| LN13 metastasis Absence | 231 | 103 | 15 | 21 | 40 | 52 | 0.473 | 287 | 123 | 18 | 26 | 55 | 65 | 0.197 |
| LN13 metastasis Presence | 71 | 26 | 3 | 5 | 17 | 20 | Presence | 115 | 56 | 6 | 11 | 23 | 31 |

(Continued)
| Characteristics                      | Diagnosis of progression | Characteristics                      | Diagnosis of progression |
|-------------------------------------|--------------------------|-------------------------------------|--------------------------|
|                                     | N                        | Absence                             | 2–6 M | 6–12 M | 12–24 M | >24 M | P      | N          | Absence   | 2–6 M | 6–12 M | 12–24 M | >24 M | P      |
| LN14 metastasis Absence            | 281                      | 122                                 | 16    | 26     | 52      | 65    | 0.402  | 197       | 89        | 13     | 16     | 36      | 43    | 0.659  |
| LN15 metastasis Absence            | 294                      | 127                                 | 18    | 26     | 56      | 67    | 0.129  | 100       | 39        | 10     | 9      | 20      | 22    | 0.296  |
| LN16 metastasis Absence            | 284                      | 127                                 | 18    | 26     | 52      | 61    | 0.001  | 36        | 17        | 5      | 1      | 7       | 6     | 0.135  |
| LN17 metastasis Absence            | 293                      | 124                                 | 18    | 26     | 54      | 71    | 0.498  | 65        | 31        | 6      | 2      | 11      | 15    | 0.277  |
| LN18 metastasis Absence            | 296                      | 126                                 | 18    | 26     | 54      | 72    | 0.234  | 206       | 90        | 14     | 16     | 26      | 50    | 0.706  |
| Positive LN number 0               | 173                      | 83                                  | 12    | 17     | 26      | 35    | 0.046  | 0         |           |        |        |         |       |        |
|                                    | 1–3                      | 95                                  | 36    | 5      | 8       | 24    | 22     | 1         | 67        | 23     | 4      | 7       | 11    | 0.677  |
| Positive LN number >3              | 34                       | 10                                 | 11    | 1      | 7       | 15    | 2      | 33        | 13        | 2      | 3      | 8       | 7     |        |
| Pancreatic membrane invasion       | 284                      | 81                                  | 15    | 13     | 36      | 39    | 0.147  | 280       | 124       | 18     | 23     | 53      | 62    | 0.061  |
| Tumor size (cm) ≤2                | 118                      | 48                                  | 3     | 13     | 21      | 33    | >10    | 22        | 5         | 0      | 3      | 4       | 10    |        |
|                                    | 2–4                      | 146                                 | 60    | 8      | 10      | 36    | 32     | 46        | 19        | 2      | 4      | 12      | 9     | 0.704  |
|                                    | >4                       | 68                                  | 21    | 4      | 6       | 12    | 25     | 256       | 110       | 16     | 22     | 45      | 63    |        |
| Tumor differentiation Well         | 2                       | 0                                   | 0     | 0      | 1       | 1     | 0.035  | 202       | 93        | 12     | 16     | 38      | 43    | 0.465  |
|                                    | Moderate                 | 153                                 | 72    | 14     | 12      | 30    | 25     | 59        | 34        | 4      | 5      | 5       | 11    | 0.063  |
|                                    | Poor                     | 147                                 | 57    | 4      | 14      | 26    | 45     | 243       | 95        | 14     | 21     | 52      | 61    |        |
| Macrovacular invasion Absence      | 273                      | 120                                 | 16    | 23     | 54      | 60    | 0.161  | 205       | 97        | 14     | 17     | 37      | 40    | 0.054  |
|                                    | Presence                 | 29                                  | 9     | 2      | 3       | 3     | 12     | 97        | 32        | 4      | 9      | 20      | 32    |        |
| Microvascular invasion Absence     | 206                      | 87                                  | 15    | 19     | 40      | 45    | 0.493  | 283       | 120       | 16     | 25     | 54      | 68    | 0.871  |
|                                    | Presence                 | 96                                  | 42    | 3      | 7       | 17    | 27     | 19        | 9         | 2      | 2      | 3       | 4     |        |
| Lymph vessel invasion Absence      | 140                      | 65                                  | 8     | 12     | 21      | 34    | 0.296  | 160       | 78        | 10     | 14     | 21      | 37    | 0.061  |
|                                    | Presence                 | 162                                 | 62    | 11     | 13      | 38    | 38     | 142       | 51        | 8      | 12     | 36      | 35    |        |

M, month; LN, lymph node metastasis; LNR, lymph node ratio; TNM, tumor-node-metastasis; PI, prognostic index; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; PNI, prognostic nutritional index; SII, systemic immune-inflammation index; mGPS, modified Glasgow Prognostic Score; WBC, white blood cell; ALB, albumin; CRP, C-reactive protein; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; HBV, hepatitis B virus; PDAC, pancreatic ductal adenocarcinoma.
Risk Factors for Progression-Free Survival and Overall Survival

For all included patients, 1-, 2-, and 3-year OS and PFS were 81.3, 58.4, and 47.0% and 49.7, 36.0, and 29.7%, respectively. In order to investigate the prognostic factors of survival, a total of 48 high-dimensional radiological and pathological data were incorporated in the LASSO regression (Figure 5). Three best predictors for OS, including LN16 metastasis, tumor differentiation, and imaging tumor size, and another eight predictors for PFS, including the eighth edition tumor–node–metastasis (TNM) stage, liver-only metastasis, lung-only metastasis, local progression, multiple metastases, LN16 metastasis, imaging tumor size, and LNR, were identified. The predictors selected by LASSO regression, along with the associated clinical factors identified by a univariate analysis, were incorporated to the multivariable analysis. Subsequent analyses illustrated that decreased time interval to progression (HR = 4.30, 95% CI 2.57–7.20, P < 0.001), elevated CA19-9 level (HR = 1.78, 95% CI 1.25–2.53, P = 0.002), local progression (HR = 8.84, 95% CI 5.25–14.87, P < 0.001), liver-only metastasis (HR = 14.74, 95% CI 9.12–23.84, P < 0.001), lung-only metastasis (HR = 9.41, 95% CI 4.45–19.91, P < 0.001), local + distant progression (HR = 11.69, 95% CI 5.79–23.58, P < 0.001), multiple metastases (HR = 19.51, 95% CI 8.78–43.38, P < 0.001), LN16 metastasis (HR = 3.04, 95% CI 1.58–5.99, P < 0.001), imaging tumor size (HR = 1.76, 95% CI 1.16–2.67, P = 0.008), chemotherapy (HR = 0.60, 95% CI 0.42–0.86, P = 0.005), and TNM stage (HR = 2.40, 95% CI 1.17–4.92, P = 0.017) (Table 5).

Performance of Prediction for Overall Survival and Progression-Free Survival

The comparisons of ROC curves of the predictive systems on the basis of the risk factors and TNM stage system are shown in Figure 6. The values of AUC for 1-, 2-, and 3-year OS and PFS prediction were 0.823, 0.844, and 0.858 and 0.789, 0.829, and 0.863, respectively, which were significant higher than those for reduced OS (Table 4).
He et al. Predicting Recurrence Risk of PDAC

Figure 3 | Pairwise comparison of overall survival for different tumor progression patterns. (A) Stratification of patients using different progression patterns of progression free, local, liver only, lung only, others, local and distant and multiple progressions. (B–P) Stratification of patients by comparing the following patterns of progression: local vs. liver only, local vs. lung only, local vs. others, local vs. local + distant, local vs. multiple, liver only vs. lung only, liver only vs. others, liver only vs. local + distant, liver only vs. multiple, lung only vs. others, lung only vs. local + distant, lung only vs. multiple, others vs. local + distant, others vs. multiple and local + distant vs. multiple.

of the TNM stage system (OS, 1 year, 0.614; 2 years, 0.592; 3 years, 0.599; PFS, 1 year, 0.669; 2 years, 0.647; 3 years, 0.630). The predictive system also demonstrated significantly more valuable prediction performance with the C-indexes of 0.829 (95% CI 0.760–0.898) for OS and 0.797 (95% CI 0.723–0.871) for PFS, respectively, than did the TNM stage system (C-index, OS, 0.588 [95% CI 0.465–0.711]; PFS, 0.619 [95% CI 0.524–0.713]).

Discussion

Pancreatic cancer has an extremely poor prognosis even after surgical resection. Recurrence was observed in more than 60% of all PDAC patients after surgery (4, 16) and remained the main reason of poor prognosis in these patients. In this study, recurrence was observed in 57.3% of patients. In addition, 68.2% of recurrences occurred at a distant site, illustrating that there were systemic diseases in these patients at the time of surgery. Also, 41.6% of recurrences occurred 2 years after surgery. Maybe recurrence-free survival for 2 years did not mean cure, and regular follow-up was also needed for these patients. Furthermore, it was shown that different time intervals or patterns of recurrence would both have different survival. These results suggested that maybe recurrence time interval and patterns were important aspects of recurrence, and the evaluation of factors associated with time intervals and patterns of recurrence opened the door to the exploration of unique biological behaviors of PDAC.

Although the prognostic value of recurrence in survival had been illustrated by previous studies, the current published results differed considerably. For instance, the recurrence rates of PDAC patients after surgery ranged from 38 to 88% in previous studies (17–21). The discrepancies might differ greatly owing to the variations of neoadjuvant treatment regimen and differences of time periods of follow-up. Additionally, the patterns and timing of recurrence of PDAC patients were also not clearly illustrated owing to small population size and limited period of follow-up (22, 23). Moreover, only “local,” “distant,” and “local + distant” groups were analyzed in most of these studies (8, 9, 24–26), and specific recurrence sites were seldom illustrated. In the present study, our detailed recurrence data allowed for further stratification of recurrence patterns in six separated groups: local, liver-only, lung-only, other, local + distant, and multiple metastases. Similar with those in other studies (27, 28), liver-only metastasis and local recurrence contributed to most of the disease progressions. Considering the time period to tumor progress, our study further illustrated that liver-only metastasis
FIGURE 4 | Pairwise comparison of progression-free survival for different tumor progression patterns. (A) Stratification of patients using different progression patterns of progression free, local, liver only, lung only, others, local and distant and multiple progressions. (B–P) Stratification of patients by comparing the following patterns of progression: local vs. liver only, local vs. lung only, local vs. others, local vs. local + distant, local vs. multiple, liver only vs. lung only, liver only vs. others, liver only vs. local + distant, liver only vs. multiple, lung only vs. others, lung only vs. local + distant, lung only vs. multiple, others vs. local + distant, others vs. multiple and local + distant vs. multiple.

Progression patterns and time period were two important natural aspects of progression. Apart from the changes of progression patterns over time, it was shown that survival differences were significant when they were stratified by different sites of first recurrence and time periods to tumor progression. In the current study, liver-only metastasis led to the shortest median PFS of only 5.1 months, which was comparable with that of local + distant progression or multiple metastases. Owing to the high rates of occurrence, liver-only metastasis contributed to most of the local + distant progression and multiple metastases. This may partly explain the similar PFS among these three patterns of progression. Similar results were also observed in a study conducted by Suenaga et al. (3), which reported that the median PFS of PDAC patients after surgery was 6.0 months. Apart from liver-only and lung-only metastases, other sites of sole metastasis contributed the longest median PFS (median 12.7 months) among all patterns of progression, followed by local recurrence with a median PFS of 9.0 months. A similar result was also achieved in Vincent's study (4). Additionally, survival differences of OS and PPS were also explored in the present study. Compared with patients with liver-only metastasis, although patients with other sites of distant metastases had slightly short median PPS, they finally achieved longer median OS owing to the significantly extended PFS. Moreover, compared with other patterns of progression, local recurrence contributed to better OS, followed by other sites of sole metastasis, and better PPS, followed by lung-only metastasis. A complete understanding of why local recurrence and lung-only metastasis were associated with relatively favorable PPS remains elusive. A hypothesis assumed that the large capacity of tumor bed and lung allowed patients to endure a greater tumor burden, leading to extended survival (29). Considering the slow growth pattern and apparently less aggressive tumor biology of local progression and lung-only metastasis, maybe locally advanced pancreatic cancer (LAPC) patients can benefit from additional treatment of the subsequent lung and local recurrence after surgery. Additionally, the inherent nature of organ-specific metastasis might be explained by the distinct genetic signatures of both primary PDAC and metastatic lesions. The analysis of biological mechanisms would potentially provide personal therapeutic approaches.
| Characteristics | Univariate analysis | Multivariate analysis | Characteristics | Univariate analysis | Multivariate analysis |
|-----------------|---------------------|----------------------|-----------------|---------------------|----------------------|
| Age             |                     |                      | Perineural invasion |                     |                      |
| ≤ 60 years      | Reference 0.951     |                      | Absence          | Reference 0.188     |                      |
| > 60 years      | 1.02 0.52–2.01      |                      | Presence         | 1.59 0.80–3.16      |                      |
| Gender          | Female 0.897        |                      | Adjacent organ invasion |         |                      |
| Male            | 1.05 0.52–2.09      |                      | Absence          | 0.96 0.32–2.90      |                      |
| LN metastasis   | Absence 0.060       |                      | NI              | 0.188               |                      |
| Presence        | 1.92 0.97–3.28      |                      | LNR 0           | 1.36 0.91–2.04      | 0.135                |
| LN5 metastasis  | Absence 0.060       |                      | Presence        | 1.50 0.70–3.22      | 0.302                |
| Presence        | –                   |                      | Satellite foci | Reference 0.470     |                      |
| LN6 metastasis  | Absence 0.060       |                      | Absence         | 0.47 0.06–3.66      |                      |
| Presence        | –                   |                      | Tumor site      | Reference 0.964     |                      |
| LN7 metastasis  | Absence 0.783       |                      | Body and tail  | 0.98 0.41–2.35      |                      |
| Presence        | 1.36 0.15–11.94     |                      | Imaging tumor size (cm) ≤ 2 |        |                      |
| LN8 metastasis  | Absence 0.060       |                      | 2–4             | 1.74 0.79–3.85      | 0.173                |
| Presence        | –                   |                      | > 4             | 1.32 0.48–3.67      | 0.600                |
| LN9 metastasis  | Absence 0.060       |                      | Imaging LN metastasis Absence | Reference 0.213 |                      |
| Presence        | –                   |                      | Presence        | 1.54 0.78–3.01      |                      |
| LN10 metastasis | Absence 0.913       |                      | Imaging vascular invasion Absence | Reference 0.203 |                      |
| Presence        | 1.13 0.13–9.62      |                      | Presence        | 1.62 0.77–3.40      |                      |
| LN11 metastasis | Absence 0.315       |                      | Imaging LN size (cm) ≤ 0.5 |        |                      |
| Presence        | 2.32 0.45–11.90     |                      | Presence        | 0.63 0.23–1.75      | 0.374                |
| LN12 metastasis | Absence 0.163       |                      | Pi > 1          | 2.01 0.94–4.32      | 0.073                |
| Presence        | 1.91 0.77–4.75      |                      | Reference       | 0.94 0.43–2.06      | 0.878                |
| LN13 metastasis | Absence 0.460       |                      | Presence        | 1.86 0.57–6.04      | 0.304                |
| LN14 metastasis | Absence 0.389       |                      | NLR ≤ 3.32      | Reference 0.203     |                      |
| Presence        | 1.65 0.53–5.29      |                      | Presence        | 0.61 0.29–1.31      |                      |
| LN15 metastasis | Absence 0.32        |                      | dNLR ≤ 3.32     | Reference 0.067     |                      |
| Presence        | –                   |                      | Presence        | 0.53 0.27–1.06      |                      |
| LN16 metastasis | Absence 0.814       |                      | PLR ≤ 98.13     | Reference 0.731     |                      |
| Presence        | 0.83 0.18–3.78      |                      | Presence        | 1.21 0.40–3.64      |                      |

(Continued)
| Characteristics                              | Univariate analysis | Multivariate analysis | Characteristics                              | Univariate analysis | Multivariate analysis |
|---------------------------------------------|---------------------|-----------------------|---------------------------------------------|---------------------|-----------------------|
|                                             | HR      | 95%     | P    | HR      | 95%     | P    |                                             | HR      | 95%     | P    |                                             | HR      | 95%     | P    |
| LN17 metastasis Absence                    | Reference          | 0.870               |     | Nl      | PNI     | 0    | LN17 metastasis Presence                    | 0.64    | 0.10–6.90 | 1    | LN17 metastasis Presence                   | 2.64    | 0.90–7.73 | NI   |
| LN18 metastasis Absence                    | Reference          | 0.018               |     | Reference| 0.017  | ≤1,000| LN18 metastasis Presence                    | 7.22    | 1.40–37.15 | 8.97 | LN18 metastasis Presence                   | 0.51    | 0.23–1.16 | NI   |
| Positive LN number                         | Reference          | 0.432               |     | Nl      | mGPS    | 0    | Positive LN number                         | 1       | 0.37–1.53 | 1    | Positive LN number                         | 1.01    | 0.50–2.07 | NI   |
| Pancreatic membrane invasion Presence      | 1.72    | 0.82–3.63 | 0.154| 0.92    | 0.39–2.14 | 0.843| Pancreatic membrane invasion Presence      | 1.82    | 0.66–5.06 | 0.250| Pancreatic membrane invasion Presence      | 1.21    | 0.43–3.41 | 0.720|
| Pancreatic membrane invasion Presence      | 1.09    | 0.36–3.31 | 0.555| 1.56    | 0.78–3.12 | 0.288| Pancreatic membrane invasion Presence      | 1.21    | 0.59–2.74 | 0.462| Pancreatic membrane invasion Presence      | 0.19    | 0.08–0.43 | 0.18  | Pancreatic membrane invasion Presence      | 0.08    | 0.08–0.42 | 0.08  |

**TABLE 2 | Continued**

PDAC, pancreatic ductal adenocarcinoma; HR, hazard ratio; LNR, lymph node ratio; LN, lymph node metastasis; NLR, neutrophil-to-lymphocyte ratio; dNLR, derived neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; PNI, prognostic nutritional index; SII, systemic immune-inflammation index; mGPS, modified Glasgow Prognostic Score; WBC, white blood cell; ALB, albumin; CRP, C-reactive protein; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; HBV, hepatitis B virus.
TABLE 3 | Risk factors for liver metastases in PDAC patients after surgery.

| Characteristics | Univariate analysis | Multivariate analysis | Characteristics | Univariate analysis | Multivariate analysis |
|-----------------|---------------------|-----------------------|-----------------|---------------------|-----------------------|
|                 | HR | 95% | P   | HR | 95% | P   |                 | HR | 95% | P   |                 | HR | 95% | P   |
| Age             |     |     |     |     |     |     |     |                 |     |     |     |                 |     |     |     |
| ≤60 years       | Reference | 0.030 | Reference | 0.031 | Perineural invasion | Absence | Reference | 0.145 | NI |     |     |                 |     |     |     |
| >60 years       | 1.32 | 1.11–2.23 | 1.35 | 1.21–1.73 | Presence | Reference | 1.59 | 0.85–2.97 | NI |     |     |                 |     |     |     |
| Gender          | Female | Reference | 0.922 | Ni |     |     |     |     |     |     |     |                 |     |     |     |
| Male            | 1.03 | 0.55–1.93 | Reference | 0.145 | NI |     |     |     |     |     |     |                 |     |     |     |
| LN metastasis   | Absence | Reference | 0.901 | Ni |     |     |     |     |     |     |     |                 |     |     |     |
| Presence        | 1.04 | 0.56–1.93 | Reference | 0.160 | NI |     |     |     |     |     |     |                 |     |     |     |
| LN5 metastasis  | Absence | Reference | 0.901 | Ni |     |     |     |     |     |     |     |                 |     |     |     |
| Presence        | –     |     |     |     |     |     |     |     |     |     |     |                 |     |     |     |
| LN6 metastasis  | Absence | Reference | 0.636 | Ni |     |     |     |     |     |     |     |                 |     |     |     |
| Presence        | 1.74 | 0.18–17.04 | Reference | 0.402 | NI |     |     |     |     |     |     |                 |     |     |     |
| LN7 metastasis  | Absence | Reference | 0.269 | Ni |     |     |     |     |     |     |     |                 |     |     |     |
| Presence        | 2.65 | 0.47–14.88 | Reference | 0.489 | NI |     |     |     |     |     |     |                 |     |     |     |
| LN8 metastasis  | Absence | Reference | 0.500 | Ni |     |     |     |     |     |     |     |                 |     |     |     |
| Presence        | 1.75 | 0.34–8.95 | Reference | 0.489 | NI |     |     |     |     |     |     |                 |     |     |     |
| LN9 metastasis  | Absence | Reference | 0.743 | Ni |     |     |     |     |     |     |     |                 |     |     |     |
| Presence        | 1.30 | 0.27–6.33 | Reference | 0.489 | NI |     |     |     |     |     |     |                 |     |     |     |
| LN10 metastasis | Absence | Reference | 0.803 | Ni |     |     |     |     |     |     |     |                 |     |     |     |
| Presence        | 0.85 | 0.24–3.01 | Reference | 0.836 | Ni |     |     |     |     |     |     |                 |     |     |     |
| LN11 metastasis | Absence | Reference | 0.773 | Ni |     |     |     |     |     |     |     |                 |     |     |     |
| Presence        | 0.73 | 0.09–6.09 | Reference | 0.53 | NI |     |     |     |     |     |     |                 |     |     |     |
| LN12 metastasis | Absence | Reference | 0.466 | Ni |     |     |     |     |     |     |     |                 |     |     |     |
| Presence        | 1.40 | 0.57–3.41 | Reference | 0.42 | NI |     |     |     |     |     |     |                 |     |     |     |
| LN13 metastasis | Absence | Reference | 0.363 | Ni |     |     |     |     |     |     |     |                 |     |     |     |
| Presence        | 1.38 | 0.69–2.73 | Reference | 0.42 | NI |     |     |     |     |     |     |                 |     |     |     |
| LN14 metastasis | Absence | Reference | 0.803 | Ni |     |     |     |     |     |     |     |                 |     |     |     |
| Presence        | 0.85 | 0.24–3.01 | Reference | 0.42 | NI |     |     |     |     |     |     |                 |     |     |     |
| LN15 metastasis | Absence | Reference | 0.018 | Reference | 0.023 | dNLR | ≤3.32 | Reference | 0.087 | NI |     |     |                 |     |     |     |
| Presence        | 5.53 | 1.34–22.93 | Reference | 0.836 | Ni |     |     |     |     |     |     |                 |     |     |     |
| LN16 metastasis | Absence | Reference | 0.050 | Reference | 0.252 | PLR | ≤98.13 | Reference | 0.379 | NI |     |     |                 |     |     |     |
| Presence        | 2.80 | 1.00–7.87 | Reference | 0.55 | NI |     |     |     |     |     |     |                 |     |     |     |
| LN17 metastasis | Absence | Reference | 0.623 | Ni |     |     |     |     |     |     |     |                 |     |     |     |
| Presence        | 1.50 | 0.30–7.42 | Reference | 0.836 | Ni |     |     |     |     |     |     |                 |     |     |     |

(Continued)
| Characteristics | Univariate analysis | Multivariate analysis | Characteristics | Univariate analysis | Multivariate analysis |
|-----------------|---------------------|----------------------|-----------------|---------------------|----------------------|
|                 | HR                  | 95%                  | P               | HR                  | 95%                  | P               | HR          | 95%          | P          |
| LN18 metastasis| Absence Reference   | Ni                    | SII             | ≤1,000              | Reference Ni         | 0.140 Ni         |               |             |             |
|                 | Presence –          |                      |                 | >1,000              | 1.61 0.86–3.02       | Ni               |               |             |             |
| Positive LN     | 0                   | Reference Ni          | mGPS 0          | 1                   | 1.38 0.67–2.83       | 0.380 Ni         |               |             |             |
| number           | 1–3                 | 1.53 0.75–3.11       | 0.245           | 2                   | 2.07 0.77–5.58       | Ni               |               |             |             |
|                 | >3                  | 2.15 0.85–6.44       | 0.105           | 1.79 0.97–3.32      | >10                   | 2.07 0.77–5.58 | Ni           |             |             |
| Pancreatic      | Absence Reference   | 0.063 Ni              |                |                     |                      |                 |               |             |             |
| membrane invasion| Presence            |                      |                 |                     |                      |                 |               |             |             |
| Tumor size (cm) | Presence ≤2         | 1.79 0.97–3.32       |               |                     |                      |                 |               |             |             |
|                 | 2–4                 | 2.37 1.03–5.47       | 0.043           | 1.97 0.83–4.68      | ≤35                   | 1.09 0.46–2.61 | Ni           |             |             |
|                 | >4                  | 2.36 0.92–6.08       | 0.074           | 1.48 0.53–4.19      | >35                   | 0.457 1.27      | 0.49–3.35   | 0.623       |             |
| Tumor           | Well                | Reference Ni          |                |                     |                      |                 |               |             |             |
| differentiation | Moderate            | 0.11 0.01–1.83       | 0.123           | CA19-9 (U/ml) ≤35   | Reference Ni         | 0.079 Ni        |               |             |             |
|                 | Poor                | 0.29 0.02–4.75       | 0.385           | >35                 | 2.07 0.90–6.32       | Ni               |               |             |             |
| Macrovascular   | Absence Reference   | 0.494 Ni              |                |                     |                      |                 |               |             |             |
| invasion        |                    |                      |                 |                     |                      |                 |               |             |             |
|                 | Presence            | 1.40 0.54–3.63       | 0.633           | >5                  | 1.15 0.60–2.19       | Ni               |               |             |             |
| Microvascular   | Absence Reference   |                      |                |                     |                      |                 |               |             |             |
| invasion        |                    |                      |                 |                     |                      |                 |               |             |             |
|                 | Presence            | 1.17 0.61–2.23       | 0.287           | Presence            | 0.27 0.04–2.09       | Ni               |               |             |             |
| Lymph vessel    | Absence Reference   |                      |                |                     |                      |                 |               |             |             |
| invasion        |                    |                      |                 |                     |                      |                 |               |             |             |
|                 | Presence            | 1.42 0.58–1.67       | 0.50            | Yes                 | 0.50 0.27–0.94       | 0.63 0.32–1.22  | Ni           |             |             |

PDAC, pancreatic ductal adenocarcinoma; HR, hazard ratio; LNR, lymph node ratio; LN, lymph node metastasis; PI, prognostic index; NLR, neutrophil-to-lymphocyte ratio; dNLR, derived neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; PNI, prognostic nutritional index; SII, systemic immune-inflammation index; mGPS, modified Glasgow Prognostic Score; WBC, white blood cell; ALB, albumin; CRP, C-reactive protein; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; HBV, hepatitis B virus.
The exploration of risk factors for organ-specific recurrences and predictive factors for survival formed another important finding of this study. Several characteristics were risk factors for liver-only metastasis, such as age older than 60 years and LN15 metastasis. Presence of specific stations of LN metastases could be interpreted as signs of increasing probabilities of progressions. LN18, LN15, and LN14 metastases were identified as predictors for local progression, local + distant metastases, and multiple metastases, respectively. Additionally, as an effective adjuvant therapy to increase survival, the effects of chemotherapy on patterns of progression were poorly understood. Similar with previous study (4), the current study showed that chemotherapy significantly reduced the likelihood of recurrence, especially for local recurrence and lung-only metastasis. Additionally, the prognostic factors were also explored. Apart from the conventional recurrence patterns, elevated levels of CEA, enlarged imaging tumor size, poor differentiation, and advanced TNM stages were all predictive factors of decreased PFS. The exact relation of poor differentiation and poor PFS remained unclear. Maybe this could be partly explained by the ability of PDAC to develop distant metastases, which could be enhanced by the molecules released by the poorly differentiated tumor, including epidermal growth factor, E-cadherin (24). On the other hand, an increasing time prior to tumor progression was also a predictive factor of improved OS, indicating more favorable tumor behavior in patients with late progression. After other risk factors were controlled, the multivariate analysis also illustrated that elevated level of CA19-9 and LN16 metastasis were significantly associated with decreased OS, suggesting that patients with these unfavorable characteristics needed to receive adjuvant therapy after surgery to earn prolonged survival. Similar with study conducted by Groot et al. (30), our results showed that chemotherapy was associated with less local progression and lung-only metastasis and was an independent predictor for PFS. However, the significant associations between chemotherapy and other patterns of recurrences were not observed, and chemotherapy failed to act as a predictor of OS in this study. Owing to the heterogeneity in the length and regimen of the chemotherapy, data on the adjuvant or neoadjuvant chemotherapy in the current literatures were often limited and contradictory. A previous study based on 1,375 patients did not
### TABLE 4 | Independent prognostic factors for OS.

| Characteristics          | Univariate analysis | Multivariate analysis |
|--------------------------|---------------------|-----------------------|
|                          | HR  | 95%            | P  | HR  | 95%            | P  |
| Age                      |     |                |    |     |                |    |
| ≤60 years                | 1.40| 0.96–2.04      | 0.084|     |                |    |
| >60 years                | 0.89| 0.61–1.31      | 0.556|     |                |    |
| Gender                   |     |                |    |     |                |    |
| Female                   | 2.43| 1.38–4.29      | 0.002| 1.73| 0.70–4.26      | 0.234|
| Male                     | 0.89| 0.61–1.31      | 0.447|     |                |    |
| WBC count                |     |                |    |     |                |    |
| ≤10                      | 1.16| 0.79–1.72      | 0.612|     |                |    |
| >10                      | 1.03| 0.69–1.54      | 0.903|     |                |    |
| NLR                      |     |                |    |     |                |    |
| ≤3.32                    | 0.93| 0.61–1.40      | 0.712|     |                |    |
| >3.32                    | 1.30| 0.81–2.08      | 0.285|     |                |    |
| dNLR                     |     |                |    |     |                |    |
| ≤3.32                    | 1.40| 0.89–2.21      | 0.143|     |                |    |
| >3.32                    | 1.03| 0.58–1.83      | 0.927|     |                |    |
| PLR                      |     |                |    |     |                |    |
| ≤98.13                   | 0.93| 0.61–1.40      | 0.712|     |                |    |
| >98.13                   | 1.30| 0.81–2.08      | 0.285|     |                |    |
| PNII                     |     |                |    |     |                |    |
| 0                        | 1.20| 0.78–1.83      | 0.412|     |                |    |
| 1                        | 2.24| 1.18–4.26      | 0.014|     |                |    |
| SII                      |     |                |    |     |                |    |
| ≤1,000                   | 0.97| 0.59–1.59      | 0.897|     |                |    |
| >1,000                   | 2.24| 1.18–4.26      | 0.014|     |                |    |
| mGPS                     |     |                |    |     |                |    |
| 0                        | 1.40| 0.89–2.21      | 0.143|     |                |    |
| 1                        | 1.03| 0.58–1.83      | 0.927|     |                |    |
| PI                       |     |                |    |     |                |    |
| 0                        | 2.45| 1.34–3.57      | <0.001| 2.67| 1.52–4.69      | <0.001|
| 1                        | 3.33| 1.35–4.37      | <0.001| 3.29| 2.00–5.43      | <0.001|
| 2                        | 4.23| 2.34–6.45      | <0.001| 4.30| 2.57–7.20      | <0.001|
| ALB (g/L)                |     |                |    |     |                |    |
| ≤35                      | 1.24| 0.84–1.84      | 0.275|     |                |    |
| >35                      | 2.72| 1.52–4.87      | 0.039| 1.92| 1.03–3.58      | 0.840|
| CRP (ng/mL)              |     |                |    |     |                |    |
| ≤3                       | 1.23| 0.54–2.81      | 0.624|     |                |    |
| >3                       | 2.45| 1.34–3.57      | <0.001| 2.67| 1.52–4.69      | <0.001|
| CA19-9 (U/ml)            |     |                |    |     |                |    |
| ≤35                      | 2.72| 1.52–4.87      | 0.039| 1.92| 1.03–3.58      | 0.840|
| >35                      | 2.45| 1.34–3.57      | <0.001| 2.67| 1.52–4.69      | <0.001|
| CEA (ng/mL)              |     |                |    |     |                |    |
| ≤5                       | 1.01| 1.00–1.02      | 0.019| 1.01| 0.68–1.61      | 0.019|
| >5                       | 1.23| 0.54–2.81      | 0.624|     |                |    |
| HBV infection            |     |                |    |     |                |    |
| Absence                  | 3.63| 1.68–7.82      | 0.001|     |                |    |
| Presence                 | 1.37| 0.91–2.06      | 0.130|     |                |    |
| Chemotherapy             |     |                |    |     |                |    |
| No                       | 1.45| 0.87–2.98      | 0.13|     |                |    |
| Yes                      | 1.15| 0.84–1.56      | 0.389|     |                |    |
| Time period to recurrence|     |                |    |     |                |    |
| (month)                  | 1.34| 0.76–1.78      | 0.267|     |                |    |

OS, overall survival; HR, hazard ratio; WBC, white blood cell; NLR, neutrophil-to-lymphocyte ratio; dNLR, derived neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; PNI, prognostic nutritional index; SII, systemic immune-inflammation index; mGPS, modified Glasgow Prognostic Score; PI, prognostic index; ALB, albumin; CRP, C-reactive protein; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; HBV, hepatitis B virus.
### TABLE 5 | Independent prognostic factors for PFS.

| Characteristics                  | Univariate analysis | Multivariate analysis |
|----------------------------------|---------------------|-----------------------|
|                                  | HR                  | 95%                   | HR                  | 95%                   | P        |
| **Age**                          |                     |                       |                     |                       |          |
| ≤60 years                        | Reference           |                       |                       |                       |          |
| >60 years                        | 1.15                | 0.85–1.55             | 0.365               |                       |          |
| Gender                           |                     |                       |                     |                       |          |
| Female                           | Reference           |                       |                       |                       |          |
| Male                             | 1.15                | 0.85–1.56             | 0.375               |                       |          |
| WBC count                        | ≤10                 | Reference             |                       |                       |          |
| >10                              | 1.73                | 1.05–2.85             | 0.032               |                       |          |
| NLR                              | ≤3.32               | Reference             |                       |                       |          |
| >3.32                            | 1.14                | 0.84–1.56             | 0.390               |                       |          |
| dNLR                             | ≤3.32               | Reference             |                       |                       |          |
| >3.32                            | 0.94                | 0.69–1.29             | 0.717               |                       |          |
| PLR                              | ≤98.13              | Reference             |                       |                       |          |
| >98.13                           | 1.32                | 0.82–2.13             | 0.256               |                       |          |
| PNI                              | 0                   | Reference             |                       |                       |          |
| 1                                | 1.25                | 0.86–1.82             | 0.244               |                       |          |
| SII                              | ≤1,000              | Reference             |                       |                       |          |
| >1,000                           | 0.96                | 0.70–1.32             | 0.813               |                       |          |
| mGPS                             | 0                   | Reference             |                       |                       |          |
| 1                                | 1.34                | 0.95–1.91             | 0.099               |                       |          |
| 2                                | 1.01                | 0.62–1.62             | 0.987               |                       |          |
| PI                               | 0                   | Reference             |                       |                       |          |
| 1                                | 1.19                | 0.85–1.66             | 0.298               |                       |          |
| 2                                | 1.68                | 0.96–2.93             | 0.069               |                       |          |
| ALB (g/L)                        | ≤35                 | Reference             |                       |                       |          |
| >35                              | 1.05                | 0.69–1.58             | 0.825               |                       |          |
| CRP (ng/L)                       | ≤3                  | Reference             |                       |                       |          |
| >3                               | 1.22                | 0.89–1.66             | 0.216               |                       |          |
| CA19-9 (U/ml)                    | ≤35                 | Reference             |                       | 0.997                |          |
| >35                              | 1.87                | 1.22–2.86             | 0.004               | 0.99                 | 0.62–1.62|
| CEA (ng/ml)                      | ≤5                  | Reference             |                       | 0.002                |          |
| >5                               | 1.60                | 1.18–2.18             | 0.003               | 1.78                 | 1.25–2.53|
| HBV infection                    | Absence             | Reference             |                       |                       |          |
| Presence                         | 0.98                | 0.52–1.86             | 0.95                |                       |          |
| Chemotherapy                     | No                  | Reference             |                       |                       |          |
| Yes                              | 1.35                | 1.00–1.82             | 0.050               | 0.60                 | 0.42–0.86|
| Local recurrence                 | Absence             | Reference             |                       |                       | <0.001   |
| Presence                         | 8.84                | 5.25–14.87            |                   |                       |          |
| Liver metastasis                 | Absence             | Reference             |                       |                       | <0.001   |
| Presence                         | 14.74               | 9.12–23.84            |                   |                       |          |
| Lung metastasis                  | Absence             | Reference             |                       |                       | <0.001   |
| Presence                         | 9.41                | 4.45–19.91            |                   |                       |          |
| Local + distant metastasis       | Absence             | Reference             |                       |                       | <0.001   |
| Presence                         | 11.69               | 5.79–23.58            |                   |                       |          |
| Multiple metastasis              | Absence             | Reference             |                       |                       | <0.001   |
| Presence                         | 19.51               | 8.78–43.38            |                   |                       |          |
| LN16 metastasis                  | Absence             | Reference             |                       |                       | 0.001    |
| Presence                         | 3.04                | 1.58–5.99             |                   |                       |          |
| Imaging tumor size (cm)           | ≤2                  | Reference             |                       |                       |          |
| >2                               | 1.76                | 1.16–2.67             | 0.008               |                       |          |
| >4                               | 1.47                | 0.83–2.58             | 0.185               |                       |          |

(Continued)
show survival benefit from adjuvant chemotherapy (31), whereas in another study, the additional survival benefit from adjuvant chemotherapy was reported in PDAC patients (32). The selection bias partly contributed to this discrepancy in retrospective study, and maybe more insights concerning the survival benefit of chemotherapy were available from prospective studies.

It is important to note that the precise prediction of progression is essential for the individual treatment. An

### TABLE 5 | Continued

| Characteristics       | Univariate analysis |          |          | Multivariate analysis |          |          |
|-----------------------|---------------------|----------|----------|-----------------------|----------|----------|
|                       | HR                  | 95%      | P        | HR                    | 95%      | P        |
| LNR                   | 0                   | 0.96     | 0.46–1.98| 0.96                  | 0.46–1.98| 0.900    |
|                       | 0–0.16              | 1.03     | 0.51–2.10| 1.03                  | 0.51–2.10| 0.928    |
|                       | >0.16               |          |          |                       |          |          |
| TNM stage             | IA                  |          |          |                       |          |          |
|                       | IB                  | 0.92     | 0.52–1.64| 0.92                  | 0.52–1.64| 0.782    |
|                       | IIA                 | 2.40     | 1.17–4.92| 2.40                  | 1.17–4.92| 0.017    |
|                       | III                 | 1.21     | 0.49–3.01| 1.21                  | 0.49–3.01| 0.674    |
|                       |                     | 1.12     | 0.50–2.50| 1.12                  | 0.50–2.50| 0.789    |
| Tumor differentiation | Well                |          |          |                       |          |          |
|                       | Moderate            | 1.24     | 0.78–1.95| 1.24                  | 0.78–1.95| 0.330    |
|                       | Poor                | 1.65     | 1.21–3.67| 1.65                  | 1.21–3.67| 0.032    |

PFS, progression-free survival; HR, hazard ratio; WBC, white blood cell; NLR, neutrophil-to-lymphocyte ratio; dNLR, derived neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; PNI, prognostic nutritional index; SII, systemic immune-inflammation index; mGPS, modified Glasgow Prognostic Score; PI, prognostic index; ALB, albumin; CRP, C-reactive protein; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; HBV, hepatitis B virus; LNR, lymph node ratio; TNM, tumor–node–metastasis.

### FIGURE 6 | Comparisons of receiver operating characteristic (ROC) curves of both the predictive system and TNM stage system for predicting 1-, 2-, and 3-year OS (A–C) and PFS (D–F) for LAPC patients after surgery, respectively. TNM, tumor–node–metastasis; PFS, progression-free survival; OS, overall survival; LAPC, locally advanced pancreatic cancer.
The important advantage of this study was the use of a relatively large cohort to determine the risk factors for different patterns of recurrences and survival. Several independent prognostic factors were selected by evaluating high-dimensional radiological and clincopathological variables in the current study. In addition, analyses of ROC curves and comparisons of the associated values of AUC and C-indexes of the predictive system and TNM stage system showed a strong predictive strength of the predictive system on the basis of risk factors for OS and PFS. The inclusion of additional clincopathological variables guaranteed that the established predictive system was better in predicting OS and PFS than did the eighth edition of the TNM stage system. On the other hand, the different clincopathological features of progression patterns and timing suggested that there might be unique biological features in different progressions. Currently, the molecular feature, SMAD4, was shown to have a close relationship with progression patterns. Tumors with SMAD4 up-regulated tended to be localized, whereas the down-regulation or silence of this gene was likely to promote metastasis (33). Moreover, different regulation of specific genes was associated closely with different patterns of progressions in an animal model (34, 35). Therefore, maybe the combination of clincopathological characteristics and genetic features would have more meaningful implications in predicting progressions. Clinicians could perform evaluation of recurrence risks and survival on the basis of individual risk factors of patients and specialize the adjuvant therapy, which fitted the current trend to personalized medicine.

This study has several limitations. First, the specific adjuvant therapies after surgery and the associated response to adjuvant therapy were unavailable. More detailed information of length and regimen of chemotherapy would further illustrate the association between therapy and progression. Second, this study only focused on the first recurrence, and subsequent progressions were not taken into account. Third, it was well-known that more progressions would be observed over time. In this study, the period of follow-up for all included patients was longer than 1 year, but this time period was not relatively long enough. Although patients were followed up with a median time of 2 years in this study, the whole view of progression in patients could be changed if patients were followed up even longer. A prospective study with an even longer period of follow-up is also needed to validate results of this study. Last, sometimes diagnoses of progression on the basis of imaging were challenging, and it was possible to overestimate the probabilities of progression in PDAC patients after surgery.

In conclusion, for PDAC patients after radical operation, the different patterns and timing of recurrence were accurately described in the present study. This study further identified the risk factors of different recurrence patterns, which could help to predict the occurrence of first tumor progression. Furthermore, individual predictors of OS and PFS were also identified and validated for these patients. These findings further suggested the linkages between different progression patterns and biological heterogeneity, and the exploration might provide new versions into the prediction of tumor progression, prognosis stratification, and a more personalized management for PDAC patients after surgery.

DATA AVAILABILITY STATEMENT

The authenticity of this article has been validated by uploading the key raw data onto the Research Data Deposit public platform (http://www.researchdata.org.cn), with the Approval Number as RDDA2019001267.

ETHICS STATEMENT

This study was approved by the Institutional Review Board of SYSUCC. All procedures performed in present study involving human participants were in accordance with the ethical standards of institutional and/or national research committees and the 1964 Declaration of Helsinki and its later amendments or similar ethical standards. Written informed consent for inclusion in this study was obtained from patients prior to treatment.

AUTHOR CONTRIBUTIONS

SL was responsible for conception, design, and quality control of this study. CH, XH, and YZ performed the study selection, data extraction, statistical analyses and were major contributors in writing the manuscript. CH and XH participated in study selection and statistical analyses. CH, XH, YZ, ZC, and XL contributed in classification criteria discussion. CH, XH, and YZ contributed to the writing of manuscript. SL reviewed and edited the manuscript. All authors have read and approved the final version of the manuscript.

FUNDING

This work was supported by grants from the National Natural Science Funds (no. 81672390) and the National Key Research and Development Plan (no. 2017YFC0910002).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2019.01197/full#supplementary-material

REFERENCES

1. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. (2014) 74:2913–21. doi: 10.1158/0008-5472.CAN-14-0155
2. Parikh AA, Maiga A, Bentrem D, Squires MH III, Kooby DA, Maithel SK, et al. Adjuvant therapy in pancreas cancer: does it influence patterns of recurrence? J Am Coll Surg. (2016) 222:448–56. doi: 10.1016/j.jamcollsurg.2015.12.031
3. Suenaga M, Fujii T, Kanda M, Takami H, Okumura N, Inokawa Y, et al. Pattern of first recurrent lesions in pancreatic cancer: hepatic relapse is associated with dismal prognosis and portal vein invasion. *Hepato Gastroenterol.* (2014) 61:1736–61. doi: 10.5734/heg136377

4. Groot VP, Rezaee N, Wu W, Cameron JL, Fishman EK, Hruban RH, et al. Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. *Ann Surg.* (2018) 267:936–45. doi: 10.1097/SLA.0000000000002234

5. Ellison LF, Wilkins K. An update on cancer survival. *Health Rep.* (2010) 21:55–60.

6. Tummers WS, Groen JV, Sibinga Mulder BG, Farina-Sarasqueta A, Morreau H, Jutte PC, et al. Is neoadjuvant therapy sufficient in resected pancreatic cancer? *Ann Surg.* (2019) 270:1806–13. doi: 10.1097/SLA.0000000000002805

7. Kim NH, Kim HJ. Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma. *Eur J Surg Oncol.* (2009) 35:600–4. doi: 10.1016/j.ejso.2008.12.006

8. Suenaga M, Fujii T, Kanda M, Takami H, Okumura N, Inokawa Y, et al. Pattern of isolated recurrence after surgery for pancreatic adenocarcinoma. *Br J Surg.* (2019) 106:988–909. doi: 10.1002/bjs.11144

9. Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. *J Am Coll Surg.* (2008) 206:833–46; discussion: 46–8. doi: 10.1016/j.jamcollsurg.2007.12.020

10. Ferrone CR, Marchegiani G, Hong TS, Ryan DP, Deshpande V, McDonnell EL, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. *Ann Surg.* (2015) 261:12–7. doi: 10.1097/SLA.00000000000008867

11. Kim HS, Jang JY, Han Y, Lee KB, Joo I, Lee DH, et al. Survival outcome and prognostic factors of neoadjuvant treatment followed by resection for borderline resectable pancreatic cancer. *Ann Surg Treat Res.* (2017) 93:186–94. doi: 10.14744/asstr.93.4.186

12. Jang JY, Han Y, Lee H, Kim SW, Kwon W, Lee KH, et al. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial. *Ann Surg.* (2018) 268:215–22. doi: 10.1097/SLA.0000000000002705

13. Zhao Y, Wang C. Clinicopathological features, recurrence patterns, and prognosis of pancreatic adenocarcinoma with normal serum CA19–9. A consecutive series of 154 cases from a single institute. *J Gastrointest Surg.* (2019) 23:11605–19:4209–44. [Epub ahead of print].

14. Li S, Xu H, Wang W, Gao H, Li H, Zhang S, et al. The systemic inflammation response index predicts survival and recurrence in patients with resectable pancreatic ductal adenocarcinoma. *Cancer Manage Res.* (2019) 11:3327–37. doi: 10.2147/CMAR.S197911

15. Shibata K, Matsumoto T, Yada K, Sasaki A, Ohta M, Kitanouko S. Factors predicting recurrence after resection of pancreatic ductal carcinoma. *Pancreas.* (2005) 31:69–73. doi: 10.1097/01.mpa.0000166998.04266.88

16. Zhang Y, Brampton AE, Kyriakides C, Bong JJ, Habib N, Ahmad R, et al. Loco-recurrence after resection for ductal adenocarcinoma of the pancreas: predictors and implications for adjuvant chemoradiotherapy. *J Cancer Res Clin Oncol.* (2012) 138:1663–71. doi: 10.1007/s00432-011-1165-7

17. Asiyamoto B, Gleisner A, Hermann JM, Choti MA, Wolfgang CL, Swartz M, et al. Determining pattern of recurrence following pancreateicoduodenectomy and adjuvant 5-fluorouracil-based chemoradiotherapy: effect of number of metastatic lymph nodes and lymph node ratio. *J Gastrointest Surg.* (2009) 13:752–9. doi: 10.1007/s11605-008-0762-x

18. Tani M, Kawai M, Miyazawa M, Hirono S, Sina S, Nishioka R, et al. Liver metastasis as an initial recurrence has no impact on the survival of patients with resectable pancreatic adenocarcinoma. *Langenbecks Arch Surg.* (2009) 394:249–53. doi: 10.1007/s00423-008-0296-4

19. Hernandez JM, Morton CA, Al-Saadi S, Huang M, Bowers C, et al. The natural history of resected pancreatic cancer without adjuvant chemotherapy. *Ann Surg.* (2010) 76:480–5.

20. Zheng B, Ohuchida K, Yan Z, Okumura T, Ohtsuka T, Nakamura M. Primary recurrence in the lung is related to favorable prognosis in patients with pancreatic cancer and postoperative recurrence. *World J Surg.* (2017) 41:2858–66. doi: 10.1007/s00268-017-4086-6

21. Groot VP, Blair AB, Gemenzits G, Ding D, Burkhardt RA, Yu J, et al. Recurrence after neoadjuvant therapy and resection of borderline resectable and locally advanced pancreatic cancer. *Eur J Surg Oncol.* (2019) 45:1674–83. doi: 10.1016/j.ejso.2019.04.007

22. de Geus SWL, Kasumova GG, Eskander MF, Ng SC, Kent TS, James Moser A, et al. Is neoadjuvant therapy sufficient in resected pancreatic cancer patients? A national study. *J Gastrointest Surg.* (2018) 22:214–25. doi: 10.1016/j.jgss.2017.09.029

23. Roland CL, Katz MH, Tseng CW, Lin H, Varadharachy GR, Shoff R, et al. The addition of postoperative chemotherapy is associated with improved survival in patients with pancreatic cancer treated with preoperative therapy. *Ann Surg Oncol.* (2019) 26(Suppl 3):S1221–8. doi: 10.1245/s10434-018-5454-x

24. Iacobuzio-Donahe CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, et al. DP44 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. *J Clin Oncol.* (2009) 27:1806–13. doi: 10.1200/CoClin.2008.17.7188

25. Morales M, Arens EJ, Urosevic J, Guim J, Fernández E, Pearth E, et al. RARE53 suppresses breast cancer lung metastasis by regulating adhesion and differentiation. *EMBO Mol Med.* (2014) 6:865–81. doi: 10.15252/emmm.201303673

26. Valiente M, Obenauf AC, Jin X, Chen Q, Zhang XH, Lee DJ, et al. Serpins promote cancer cell survival and vascular co-option in brain metastasis. *Cell.* (2014) 156:1002–16. doi: 10.1016/j.cell.2014.01.040

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 He, Huang, Zhang, Cai, Lin and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.